Dermavant

Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for the Treatment of Psoriasis

Retrieved on: 
Thursday, April 2, 2020
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, RTT, Organ systems, Medical specialties, Psoriasis, Immunology, Atopic dermatitis, Anacor, Eczema Area and Severity Index, Dermavant’s Phase 3 Program for Tapinarof in Psoriasis, Psoriasis, Dermavant

Im excited to announce the completion of enrollment for our PSOARING Phase 3 clinical trials of tapinarof for the treatment of adult plaque psoriasis, one of the largest topical programs ever undertaken in this indication, said Todd Zavodnick, Chief Executive Officer of Dermavant.

Key Points: 
  • Im excited to announce the completion of enrollment for our PSOARING Phase 3 clinical trials of tapinarof for the treatment of adult plaque psoriasis, one of the largest topical programs ever undertaken in this indication, said Todd Zavodnick, Chief Executive Officer of Dermavant.
  • Dermavant also plans to initiate Phase 3 clinical studies of tapinarof in atopic dermatitis.
  • Tapinarof previously demonstrated clinically meaningful and statistically significant responses in separate Phase 2b trials for plaque psoriasis and atopic dermatitis.
  • Dermavants pivotal Phase 3 clinical program for tapinarof in adult plaque psoriasis consists of PSOARING 1 and PSOARING 2, plus a long-term safety study.